Autoimmune Diseases

Abcuro takes $200M series C to fund KLRG1 antibody pivotal trial

Abcuro has secured the series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle disease trial ahead of a planned push to regulators.

James Waldron Feb 12, 2025 8:30am

start line beginning road path starting point journey

Cullinan CEO sets tone for bispecific's upcoming lupus readout

Feb 7, 2025 5:00am

Novartis gives up on anti-CD40 antibody to treat Sjögren's

Jan 31, 2025 5:13am

Nippon Shinyaku pays $36M for rights to near-approval IL-18 drug

Jan 27, 2025 2:30am

JPM25: Kyverna CEO sets priorities for CAR-T autoimmune biotech

Jan 13, 2025 7:30am

plan B fail reroute road path trail miss

Nkarta continues pivot to lupus by shelving lymphoma program

Nov 8, 2024 8:55am